Skip to main content

Table 2 Antibiotic susceptibility and clinical outcomes in a study of 60 patients with blood culture-proven typhoid fever

From: Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi

Variable

All patients (n = 60)

NARST (n = 47)

NASST (n = 13)

MDR-ST (n = 22)

NonMDR-ST (n = 38)

MIC ciprofloxacin, μg/mL

0.33 ± 0.21

0.37 ± 0.21*

0.17 ± 0.14*

0.37 ± 0.26

0.30 ± 0.18

MIC ceftriaxone, μg/mL

0.036 ± 0.016

0.038 ± 0.018

0.031 ± 0.01

0.033 ± 0.017

0.039 ± 0.016

Fever clearance time, days

5.1 ± 3.5

5.5 ± 3.8

3.7 ± 1.3

4.9 ± 2.7

5.3 ± 3.9

Total duration of illness, days

14.3(9.8–21)

16.3(11.4–24)*

9.6(6.8–10)*

14.5(9.3–21.4)

14.3(9.9–22)

Complications

11 (18)

11 (23)

--

2 (9)

9 (24)

  1. NARST = nalidixic acid-resistant Salmonella typhi
  2. NASST = nalidixic acid-sensitive Salmonella typhi
  3. MDR-ST = multidrug-resistant Salmonella typhi
  4. MIC = minimum inhibitory concentration
  5. -- no patients in this category
  6. * P-value < 0.05 for NARST vs. NASST; compared by independent t test or Mann-Whitney U test
  7. includes encephalopathy, hepatitis, lower gastrointestinal bleeding, meningitis and myocarditis. Presented as number (%) of patients; all other data given as mean ± SD or median (IQR)